Page 1

STORE AT + 4-8 ° C FragITZ SmartEnzymes " GENOVIS FragITZ STORE AT + 4-8 ° C 44-8 ° C FabALACTICA SmartEn Sial EXO STORE AT + 4-8 ° C SmartEnzymes " GENOVIS SialEXO STORE AT + 4-8 ° C GENOVIS STORE AT + 4-8 ° C GlycINATOR® SmartEnzymes ™ GENOVIS STORE AT + 4-8 ° C GlycINATOR® deGlycIT Smar deGlycIT ™ First Quarter Report 2021 • • . . . • Net sales rose by 37 percent to SEK 15,723 ( 11,475 ) thousand . Organic growth was 21 % . Gross profit was SEK 15,017 ( 10,977 ) thousand . Operating profit before depreciation and amortization ( EBITDA ) totaled SEK 1,958 ( loss : 847 ) thousand . Operating profit totaled SEK 551 ( loss : 1,889 ) thousand . Comprehensive income for the period totaled SEK 1,607 ( loss : 1,915 ) thousand . Comprehensive income per share , basic and diluted , totaled SEK 0.02 ( -0.03 ) . Cash flow from operating activities was SEK 3,512 ( -1,506 ) thousand . Cash and cash equivalents at the end of the period totaled SEK 45,929 ( 61,641 ) thousand . Significant events after the end of the quarter In April , Genovis and Waters entered into a collaboration to develop efficient methods for biopharmaceutical characterization . The goal of the collaboration is to develop automated workflows for rapid and accurate characterization of critical quality attributes of monoclonal antibodies and other protein - based drugs for bioprocess development , formulation , stability testing and quality control ( QC ) . Sales by quarter 2018 – 2021 25000 ( tkr ) 20000 15000 10000 5000 0 Q1-18 Q1-19 Q1-20 Q1-21 Q2-18 Q2-19 Q2-20 Q3-18 Q3-19 Q3-20 Q4-18 Q4-19 Q4-20 GENOVIS FIRST QUARTER REPORT 2021 Bioprocess Acquired sales 1